Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea

Abstract

Extending previous findings to routine practice settings, HU is being administered to the most severely ill children with SCD, many of whom had already started to develop organ-specific complications, but it is not associated with development of serious adverse events.